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Objectives: The costs of comprehensive cardiac rehabilitation are established and
compared to the corresponding costs of usual care. The effect on health-related quality of
life is analyzed.
Methods: An unprecedented and very detailed cost assessment was carried out, as no
guidelines existed for the situation at hand. Due to challenging circumstances, the cost
assessment turned out to be ex-post and top-down.
Results: Cost per treatment sequence is estimated to be approximately €976, whereas
the incremental cost (compared with usual care) is approximately €682. The cost estimate
is uncertain and may be as high as €1.877.
Conclusions: Comprehensive cardiac rehabilitation is more costly than usual care, and
the higher costs are not outweighed by a quality of life gain. Comprehensive cardiac
rehabilitation is, therefore, not cost-effective.
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Comprehensive cardiac rehabilitation (CCR), a mostly sec-
ondary prevention scheme offered to patients after a hospital
discharge on grounds of cardiac disease, is increasingly ap-
plied in Europe. Previously, cardiac rehabilitation focused
primarily on physical exercise (1;4;6;8;9), whereas CCR as
a much broader concept offers patient education, physical
training, smoking cessation, dietary advice, psychosocial
The project is part of a comprehensive health technology assessment,
financed by the Danish Centre for Evaluation and Health Technology As-
sessment. When carrying out the actual cost assessment, the personnel at the
economics unit as well as the department of cardiology at Bispebjerg Hos-
pital in Copenhagen were very helpful and supplied valuable information.
support, and risk factor management as well as clinical
follow-up. Although European cardiologists agree that CCR
should be an integrated part of cardiac care (5), studies reveal
a great potential for improving CCR services across Europe
(12;13;15).
The CCR scheme is regarded as secondary prevention
and may as such not be a natural part of hospital treatment.
In a healthcare system facing scarce resources, the decision
of whether or not to implement CCR depends on the cost
of the intervention, as well as cost-effectiveness considera-
tions. Ex ante, it is expected that CCR hospital expenditure
per patient is relatively small. It is not known whether CCR is
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actually cost-effective, compared to usual care. Internation-
ally, few studies exist. A 1997 meta-analysis (2) concentrat-
ing on years of life saved (YLS) found the cost per YLS
to be US$4.950 (∼€4,110) in 1995, rendering CCR highly
attractive according to a commonly used classification
scheme (7). A recent study in Hong Kong (14) found CCR
to be cost-saving compared to usual care. In addition, the au-
thors found a quality of life gain in CCR compared to usual
care. A British health technology assessment (3) found the
costs per patient joining the scheme to be £371 (∼€535).
Costs were not related to effects.
Ideally, a cost assessment of an intervention such as
cardiac rehabilitation would be based on observations from
a time study alongside a randomized controlled trial (RCT).
However, as no such study exists, this assessment follows an
alternative path. No guidelines exist in this field, nor have
any preceding studies provided a sufficient degree of detail
to shed light on this path.
Aim
This analysis aims to estimate the costs of comprehensive
cardiac rehabilitation in a hospital setting, to compare these
costs with the costs of usual care, and finally, to relate
incremental costs induced by comprehensive cardiac reha-




During the period 2000–03, an RCT (“DANREHAB”) aim-
ing to establish the effect of CCR on patient mortality, cardiac
morbidity, and quality of life was conducted at the department
of cardiology at Bispebjerg Hospital in Copenhagen. Patients
with coronary heart disease were randomly divided into ei-
ther the intervention group, who were offered CCR (380
patients), or the control group, who were offered usual care
(390 patients). Cases received a comprehensive intervention,
consisting of three lifestyle components (smoking cessation,
physical training, and dietary advice) as well as medical ad-
vice, for a 6-week period, while controls received ordinary
follow-up, without further specifications. Both groups were
assessed at baseline and at 12 months. For the present project,
the DANREHAB study population was examined and data
on quality of life were derived from the study.
In addition, the hospital made the following informa-
tion available: the accounts of the rehabilitation ward and
the outpatient ward where the usual care was carried out;
the accounts of the cardiology department and the accounts
concerning mutual expenditure for the entire hospital; and
average wage expenditure per staff category (i.e., physicians,
nurses, etc.).
Furthermore, the department of cardiology assisted in
describing work schedules, personnel categories, and so on.
Finally, a detailed data set from the patient administrative
system was used for the analyses of treatment schedules.
Costing
Only direct costs related to the treatment are included, that
is, all healthcare costs induced during intervention or usual
care. Healthcare costs induced subsequent to the analyzed
treatments (e.g., readmissions) are not incorporated, as these
costs are the subject of a separate analysis. Indirect costs, that
is, production losses, are not included. The cost assessment
compares the costs related to the intervention with the costs
related to usual care. Usual care is defined as “the routine
treatment.” As this concept is very wide and ill-defined, usual
care is in this context regarded as identical to the treatment
offered to the controls in the randomized study.
The cost computations are based on information from
the hospital department. As the original research project did
not include a costing component, it proved necessary to use
a top-down approach. This method is complicated by the
financial organization of the Danish healthcare system. Gen-
erally, the hospitals are tax-financed and operate on a block
grant. Therefore, no cash flows can be examined when ana-
lyzing expenditure. Costing is subdivided into remuneration
of health personnel and other operational expenditure.
Wages
Intervention Costs. The costs of the intervention
were assigned to the rehabilitation ward in the hospital, only
treating patients from the intervention group. Thus, the total
remuneration expenditure of that specific ward was assigned
to the intervention. The number of healthcare professionals
employed in the ward was established by using results from
a previous costing exercise. These figures were multiplied
by the average annual wage expenditure for each category,
which was supplied by the hospital administration. By ap-
plying this method, personnel costs other than wages, such
as pension and vacation allowances, were also included.
Usual Care Costs. The control group went for follow-
up in the cardiology outpatient ward, where they comprised
only a minor share of the patient population. To establish the
true share of the outpatient ward costs, a detailed data set from
the patient administrative system was applied in dividing the
resources spent in the outpatient ward into three categories:
those concerning cases, those concerning controls, and those
concerning all other patients. From analyses on this data
set, it is concluded that controls receive similar services as
all other outpatients. All visits were grouped by resource
use, and the distribution was quite similar among controls
and all other patients. Table 1 displays the visits, divided
into physician’s consultations and nurse visits, in the two
groups of patients. The difference between the two groups
is small and ambiguous, with a tendency toward controls
having relatively more nurse visits. The number of visits was
not a subject for analysis as controls visits were defined as
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Table 1. Composition of Visits in Control Group Compared to
All Other Outpatients
Average
2000 2001 2002 2001–02
Percentage of visits being consultation with a physician
Control group 50.7 33.2 42.9 38.0
All other patients 53.7 38.9 41.0 39.9
Percentage of visits being nurse visits
Control group 49.2 66.8 57.1 62.0
All other patients 46.0 60.5 59.0 59.8
being within 1 year from the randomization date, and no such
definition existed for the group of all other patients. On these
grounds, it is considered safe to apply the controls’ share
of the patient population as a proxy for their share of the
total ward costs. The control visits constituted 3.1 percent
of the total outpatient visits; thus, it was estimated that the
control group accounted for 3.1 percent of the outpatient ward
expenditure. Remuneration costs were established from the
same source as for the intervention group.
The inaccuracy associated with using expenditure in-
stead of costs cannot be ignored; however, it is assumed that
the two groups experience the same inaccuracy and, thus, to
some extent outbalance each other. For comparison purposes,
personnel expenditure, therefore, is used as proxy for wage
costs.
Other Current Costs
Other operational expenditure was in some categories as-
signed the specific ward; however, in other cost categories,
there was no subdivision of department or hospital expen-
diture. A system of allocation keys was developed based
on those cost components being assigned to the wards. The
relevance and scope for each allocation key was discussed
with relevant staff members at the department. An alloca-
tion key would suggest, for example, that pharmaceuticals in
the rehabilitation ward accounted for 1.3 percent of total de-
partment pharmaceuticals expenditure. The allocation keys
were then applied to total expenditure in each category to
deduce the true expenditure in these cases. Also in this cost
category 3.1 percent of the total cardiology outpatient ward
expenditure was assigned to controls. On the whole, costs
were assumed to equal expenditure, as the hospital is oper-
ated on a block budget, suggesting no cash flows exist within
the hospital. Furthermore, there are no profits or subsidies
involved in other current costs. Generally, the imprecision in
this case is minor compared to the imprecision in the case of
wages.
The study period is 3 years, from March 2000 to March
2003. Thus, the observations made in 2001 and 2002 cover
entire calendar years. The cost estimates are based, there-
fore, on the average costs from 2001 and 2002. After the
project completion in 2003, CCR became part of the treat-
ment offered to patients at the hospital. The magnitude of the
department increased, and now approximately 400 patients
embark on the treatment each year. Expenditure information
from this period of normal production (and full utilization of
capacity) is included for comparison purposes. Costs were
assessed by the same means as in the study period.
Number of Sequences in CCR
The total costs in the two categories are divided by the num-
ber of sequences to obtain the cost per sequence for compar-
ison purposes. Although this computation is based on actual
figures in the case of usual care, some ambiguity is related
to the number of sequences for cases. On average, slightly
less than 130 patients per year embarked on the treatment.
However, spare capacity remained, and due to the project
being an RCT, eligible patients had to consent to participate,
which may have reduced participation markedly. Further-
more, ineligible patients were excluded from participation.
The present analysis is based on an estimated full capacity
of 300 patients embarking on the scheme and 250 patients
completing treatment with a maximum of two absences. This
assumption is shrouded in vast uncertainty and is a topic for
sensitivity analysis. Due to the top-down approach, potential
costs of spare capacity, thus, is included in the cost measure.
Effectiveness
A cost-effectiveness analysis applies cost data, cf. above, and
a relevant effectiveness measurement. YLS is disregarded
as an effect measure because the data display a very small
mortality with insignificant difference between the groups,
as the relative risk of dying is .96 in the intervention group.
The 95 percent confidence interval ranges from .46 to 1.98,
as there are few deaths in both groups. Quality-adjusted life-
year as an effect measure is disregarded on the same grounds.
Health-related quality of life (HRQL) gains were measured
and remain useful for the effect measurement. The HRQL
gains were not discounted.
For assessment of HRQL, two approaches, based on the
EQ-5D questionnaire, were used. The questionnaire contains
a visual analogue scale (VAS). Respondents are asked to
mark their current state of health on this scale, where 1 (or
100) is the best possible health state, and 0 is the worst. The
interpretation of the score would be that a score lower than 1
leaves room for improvement of the health state.
The rationale behind the VAS score has been questioned,
especially from an economics theory perspective. It is ar-
gued that preference-weighted EQ-5D replies instead of the
VAS replies are more theoretically sound, as the preference
weights are deduced by interviews applying the time trade-
off method (10;11). The official Danish weights for EQ-5D
are used for transforming the five-dimensional replies into a
single HRQL measure.
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Only a minor subsample of the population in the
DANREHAB study received and completed the EQ-5D ques-
tionnaire: a total of 137 patients distributed evenly between
the two groups completed the questionnaire. The sample
is representative of the entire project population. Single-
measure HRQL is computed by both methods and for cases
as well as for controls. An HRQL gain for cases would be
interpreted as an effect of CCR.
Sensitivity Analysis
The components selected for sensitivity analysis are wages,
currents costs other than wages, and number of treatment
sequences. In the cost analysis, the wage item is drawn from
the hospital accounts and there is no uncertainty concerning
the number of employees or the amount of their actual re-
muneration. However, major uncertainty is related to the use
of expenditure instead of costs. On these grounds, the wage
component is included in the sensitivity analysis. For other
current costs, some assumptions were applied in the devel-
opment of allocation keys; therefore, this item is included for
sensitivity analysis. In analyzing the number of sequences,
cases were treated differently from controls, as the number
of rehabilitation sequences was based on interviews and as-
sumptions, whereas the number of usual care sequences was
drawn from the patient administrative system. It makes sense,
therefore, to attribute a greater uncertainty to the number of
sequences for cases than to the number of sequences for
controls. In addition, substituting expenditure for costs due
to the top-down approach renders the number of treatment
sequences quite important. The high estimate for number of
sequences is the one used above, 250 patients per year com-
pleting, whereas the low estimate is those 130 patients who
actually completed the treatment.
A linear, one-way sensitivity analysis was performed.
There seems to be no theoretical rationale of combining the
three items (wages, current costs other than wages, and num-
ber of sequences) in an n-way sensitivity analysis, as they are
not related.
RESULTS
Table 1 concerns the control group share of all outpatients. As
mentioned, the nature of the visits was examined to verify
the share of 3.1 percent. The difference between controls
and all other patients does not seem large from these fig-
ures; therefore, the assumption that controls constituted not
only 3.1 percent of patients but also 3.1 percent of re-
sources spent in the outpatient department seems to hold.
Table 2 shows the costs of a cardiac rehabilitation treatment
sequence.
From Table 2, it appears that the rehabilitation ward
at Bispebjerg Hospital in the study period had total current
costs at around €242,000 per year. Included in this figure is
also the ward’s share of current costs mutual for the depart-
ment or hospital but not investments or other capital costs.
It is estimated that, at full capacity, the ward can launch
treatment of between 250 and 300 patients a year. Thus, the
cost of one treatment sequence embarked upon would be
slightly less than €940. However, as not all treatments are
completed although patients are found eligible, a dropout
rate of approximately 20 percent remains. The cost per com-
pleted treatment is consequently higher, in the case with 300
patients embarking and 17 percent dropping out, the cost per
completed sequence is around €976. During the study pe-
riod, the capacity was not fully exploited, as several eligible
patients did not want to participate in a randomized study.
The cost per sequence in the study period is compared with
the cost per sequence in 2004, where CCR is offered to heart
patients as standard procedure and the department capacity
is fully used.
The cost per sequence for cardiac rehabilitation, thus,
is estimated to be approximately €976. This value refers
to the study period. However, after the completion of the
Table 2. Cardiac Rehabilitation, Costs in Euros
Year 2000 2001 2002 Average 2001–02 2004
Current costs apart from wages 29.261 37.755 36.642 37.199 66.023
Wages total [numbers in parentheses indicate no.
of employees during the project period]
196,451 205,576 208,021 206,799 374,816
Physician (1) 63,356 65,823 65,067 65,445 129,973
Nurse (1) 42,081 45,230 46,240 45,735 87,285
Physiotherapist (1) 37,722 39,164 40,020 39,592 61,579
Others (1 secretary, 1/2 dietician) 53,293 55,360 56,694 56,027 95,980
Total current costs 225,712 243,331 244,664 243,998 440,839
Costs per patient sequence
No. of patient sequences per year 97 130 130 130 420
Cost per actual sequence 2,327 1,873 1,882 1,877 1,050
Costs per sequence when 250 sequences per year 903 973 979 976
Note. Costs in 2003 are not included, as the project ended in March 2003. The department’s share of mutual expenditure at the hospital is
included in current costs. No capital costs are included. 2000 and 2004 figures are included for comparison purposes but are not part of the
analysis.
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Table 3. Usual Care Costs, Costs in Euros
Year 2000 2001 2002 Average 2001–02
Current costs apart from wages, outpatient ward 56,055 59,740 59,566 59,653
Wages total [numbers in parentheses indicate no.
of employees during the project period]
784,666 827,669 846,866 837,268
Physicians (4) 282,434 305,050 310,435 307,743
Nurses (8) 260,328 270,956 280,758 275,857
Others (8 secretaries) 241,903 251,663 255,673 253,668
Total current costs, outpatient ward
840,721 887,409 906,433 896,921
Control group share (3,1 percent) 26,146 27,598 28,190 27,894
Costs per sequence (95 per annum) 275 290 297 294
randomized study, the capacity of the rehabilitation ward has
been extended and the budget is correspondingly higher. In
2004–05, all current costs amount to €440,000 per annum,
computed by the same principles as in Table 2. Almost 500
patients embark on rehabilitation per annum, and 420 com-
plete the sequence. These figures render an average cost per
treatment of €1,050.
The total costs for the outpatient ward and the derived
costs for usual care patients are displayed in Table 3. In the
top of the table, current costs are computed, using the exact
same method as for the intervention costs in Table 3. Below
the total current cost results in the table, these are sized to fit
the small share of patients participating in the study. Only 3.1
percent of outpatients were part of the control group in the
randomized study. Included in this figure are only contacts
by controls during the 12 months following randomization.
Table 4 presents the results of the HRQL assessment
for both approaches. It appears that there is a clear and al-
most significant difference in HRQL in favor of CCR when
measured on the VAS scale, whereas cases and controls have
approximately the same HRQL when using the preference-
weighted method, any visible difference being in favor of
controls, as cases have an average HRQL of .817 and con-
trols have an average HRQL of .822.
The sensitivity analysis did not alter results considerably
with regard to wage costs or other current costs. The largest
uncertainty in the cost computation remains the number of
patient sequences in the rehabilitation group. The low esti-
mate is 130 patients completing per year, whereas the high
estimate is the one applied above. Applying the low estimate
renders the cost per sequence for cases €1,877, or close to
twice the cost per sequence under the high estimate of 250
completed sequences per year.
DISCUSSION
Cardiac rehabilitation is found to be more costly than usual
care, with an additional cost of €682 per sequence. The total
cost per sequence is found to be€976. The quality of life gain
is uncertain, as CCR results in a minor HRQL gain or no gain
at all, depending on the applied measure. On the basis of the
intervention costs, therefore, it is likely that CCR is not cost-
effective. Although the estimated cost of usual care is rather
reliable, this reliability does not apply to the estimated cost
of CCR. Therefore, the actual magnitude of the additional
cost of CCR compared with usual care is uncertain; however,
it can be safely concluded that CCR is more costly than usual
care.
The costs of CCR and usual care are established by
means of a top-down approach, taking into account any in-
formation with relevance for the two types of treatment. An
alternative approach would be the application of DRG prices
to the value of CCR visits and usual care visits. The Danish
DRG system applies a set of prices to somatic treatment,
based on bottom-up cost studies. However, in the field of
CCR and usual care, the applicable DRG price would be
the same, that is, the standard price per visit, approximately
€180. The only difference between CCR and usual care is
consequently the number of visits, which, again renders CCR
more costly than usual care.
The overall finding regarding the costs of CCR corre-
sponds well with the British health technology assessment
Table 4. Health-Related Quality of Life
Cases (N = 68) Controls (N = 69) Difference
t-test of
equality (p)
Average VAS score .710 .657 .057 .06
Average preference-weighted
EuroQol score
.817 .822 −.005 .44
VAS, visual analogue scale.
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(3); however, the Hong Kong study (14) rendered more
agreeable results from a CCR point of view. It is likely that
the present setting is more comparable with a British setting
than a Chinese one. Regarding effects, no comparable results
exist.
The results presented should be interpreted with some
caution, as major methodological problems persist. Most no-
tably, the applied top-down setting suggests some uncertainty
compared to the preferable bottom-up approach, including
the use of expenditure figures as cost estimates. The cost-
ing methodology may influence the conclusion regarding the
cost-effectiveness of CCR, as would the inclusion of other di-
rect costs, notably healthcare costs outside the rehabilitation
ward.
Future research ought to look into the effect of CCR on
readmissions, 3- to 5-year mortality, or any morbidity-related
effect measure. The most urgent need for research in the area
of costs of CCR remains the bottom-up cost study.
CONCLUSION
The cost analysis showed, that cost per sequence is higher
for cases than for controls. The magnitude of the difference,
however, is uncertain. Whether CCR has a positive effect on
life expectancy or use of the healthcare system remains to be
established.
POLICY IMPLICATIONS
The results, however uncertain, point to the conclusion that
cardiac rehabilitation should not be implemented in a hospital
setting, as hospitals are better off providing usual care. Thus,
cardiac rehabilitation, if implemented, should take place out-
side hospitals.
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